Bio X Cell launched a ready-to-use, anti-mouse trispecific antibody in a PD-L1 × TIGIT × LAG3 format to enable combinatorial checkpoint studies in standard preclinical models. The company said the tetravalent design lets investigators interrogate three immune pathways within one reagent, reducing the variability and complexity of multi-agent experiments. The product is engineered as a murine IgG2a constant-region antibody to fit common mouse model workflows, and Bio X Cell positioned it as an in vivo-ready reagent with ultra-pure, carrier-free formulation and low endotoxin levels. The launch comes as checkpoint combinations continue to gain clinical validation across oncology programs. If adopted widely, this type of catalog immunology tooling can speed experimental iteration for translational groups looking to benchmark synergy and immune exhaustion biology under controlled dosing conditions.